Anselamimab reduces mortality and cardiovascular hospitalisation in kappa light chain AL amyloidosis

CD19 CD22 bispecific CAR T cell therapy achieves high response rates in R/R large B cell lymphoma

Subcutaneous blinatumomab plus TKI drives high remission in relapsed Ph+ acute lymphoblastic leukaemia

ATG vs PTCy for GVHD prophylaxis in AlloHCT shows improved survival in donor haematopoietic cell transplantation

Arsenic trioxide plus all trans retinoic acid improves QoL and reduces fatigue in high risk acute promyelocytic leukaemia

Pirtobrutinib plus venetoclax rituximab improves PFS in previously treated CLL and SLL

Selinexor plus ruxolitinib improves spleen response and survival in Janus kinase inhibitor naïve myelofibrosis

Fatigue in adult ITP is common despite adequate platelet counts and minimal bleeding

Surovatamig plus rituximab induces high complete response rates in previously untreated follicular lymphoma

Romiplostim thrombopoietin receptor agonist rapidly restores platelet counts in acute ITP in 1L treatment during COVID 19

Risk model predicts relapse after frontline blinatumomab in paediatric B-ALL

Epcoritamab induces deep and durable responses in chemotherapy-ineligible elderly patients with diffuse large B-cell lymphoma